Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Purchased by Maverick Capital Ltd.

Maverick Capital Ltd. increased its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 12.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,854,488 shares of the company’s stock after buying an additional 210,764 shares during the period. Maverick Capital Ltd. owned about 1.24% of Centessa Pharmaceuticals worth $73,660,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in shares of Centessa Pharmaceuticals by 1,017.7% during the 4th quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock worth $6,593,000 after acquiring an additional 240,039 shares in the last quarter. Royce & Associates LP raised its holdings in Centessa Pharmaceuticals by 46.7% during the fourth quarter. Royce & Associates LP now owns 362,873 shares of the company’s stock worth $9,075,000 after purchasing an additional 115,486 shares during the last quarter. Sofinnova Investments Inc. acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $27,618,000. B. Metzler seel. Sohn & Co. AG purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth $961,000. Finally, GSA Capital Partners LLP grew its holdings in Centessa Pharmaceuticals by 76.5% in the fourth quarter. GSA Capital Partners LLP now owns 33,104 shares of the company’s stock valued at $828,000 after purchasing an additional 14,343 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $40.50 on Tuesday. The stock has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $12.74 and a 12-month high of $40.56. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. The firm’s 50-day moving average is $40.16 and its two-hundred day moving average is $33.89.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on CNTA. Leerink Partners downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their price target for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a report on Monday, April 13th. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Needham & Company LLC downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.